Skip to main content

Table 3 Dosage and outcomes in selected AR studies

From: The Immunomodulatory mechanism and research progress of mesenchymal stem cells in the treatment of allergic rhinitis

Study

MSC Source

Dose (cells)

Route

IgE Reduction

Adverse Events

Cho et al. (2014)[38]

ASCs

2 × 10⁶

Intravenous

60%

None reported

Kan et al. (2020)[33]

hUC-MSCs

1 × 10⁷

Intraperitoneal

75%

Transient hepatotoxicity

Zhao et al. (2022)[37]

BM-MSCs

5 × 10⁶

Intranasal

70%

Mild nasal irritation

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512